-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Minxiang Pharmaceutical issued an announcement stating that it intends to sell 100% equity of Tianjin Taishikang Medical Technology Co.
, Ltd.
(hereinafter referred to as Taishikang), a subsidiary of its medical consumables business, to its controlling shareholder Tianjin Kaierling Group Co.
, Ltd.
at a transaction price of 130 million.
Yuan
.
Public information shows
.
Established in 2011, Taishikang's main business is the production and sales of hemodialysis concentrates, dry hemodialysis powders, and disinfectants
.
From the perspective of financial data, the announcement shows that as of September 30 this year, Taishikang's net assets were 67,985,500 yuan.
In the first three quarters of this year, Taishikang's operating income and net profit were 78,686,700 yuan and 4.
5164 million yuan, respectively
.
Regarding the reason for the sale of Taishikang, Minxiang Pharmaceutical stated that it was due to changes in the market situation of centralized procurement of medical consumables and the company's plan to focus on the pharmaceutical sector
.
In this regard, the industry believes that the divestiture of subsidiaries in recent years has long been the norm for domestic pharmaceutical companies
.
With the continuous release of policies such as national procurement, mass procurement, consistency evaluation, and drug approval reforms, China's pharmaceutical industry is facing increasingly fierce market competition, which has prompted the concentration of China's pharmaceutical industry to continue to increase; As a result, a large number of pharmaceutical companies have also begun to focus on the development of their main business and enhance their core competitiveness by selling or divesting assets that are not in line with their own strategic development
.
In the recent past, in addition to Minxiang Pharmaceutical, a large number of companies are also accelerating their "weight reduction", among which operations such as dissolving subsidiaries and selling equity have continued
.
As some time ago, Renfu Pharmaceutical announced that it intends to liquidate its 2.
52% of Huatai Insurance equity held by 1.
026 billion yuan, corresponding to 102 million shares, and the transfer price is 1.
026 billion yuan
.
The transferee this time is "Anda"
.
It is understood that as early as August 1996, Huatai Insurance conducted an angel round of financing.
For the purpose of this equity transfer, Renfu Medicine stated that it was to implement the "refocusing focus", to promote business focus on asset optimization, and gradually withdraw from the competitive advantage.
Or subdivided areas with weaker synergy
.
It is worth mentioning that it has successively sold business-related assets such as medical services and gender health.
.
In the same month, Eastern Sunshine Technology also issued an announcement stating that it intends to sell 226 million domestic shares to Guangyao Pharmaceutical, and plans to sell 226 million H-share "fully-tradable" shares to Guangyao's wholly-owned subsidiary, Hong Kong Eastern Sunshine
.
The above two transactions totaled 452 million shares, accounting for approximately 51.
41% of Dongyang Sunshine Pharmaceuticals' total share capital
.
The transaction price was 3.
723 billion yuan
.
In addition, Dongyang Sunshine also stated that the company will no longer engage in the production and sales of pharmaceutical-related products; Actively expand new business in the field of new energy such as variable frequency energy storage and new energy vehicles
.
Public information shows that Dongyang Pharmaceutical is a subsidiary of Dongyang Pharmaceutical and has been focusing on drug development, production and drug sales in China.
The products cover Antiviral, endocrine, cardiovascular and other disease treatment fields
.
On August 31 this year, Tosun has issued an announcement revealing that it is planning a major asset sale and intends to transfer to Guangdong Dongyang Pharmaceutical Co.
, Ltd.
and/or its holding subsidiaries It holds no more than 51.
41% equity of Dongyang Sun Pharmaceutical
.
The industry expects that as the concentration of the pharmaceutical industry will continue to increase, market competition will become increasingly fierce; domestic and foreign pharmaceutical companies will continue to accelerate their adjustments to strategic planning, resulting in mergers and acquisitions, Activities such as restructuring will also become more frequent
.
, Ltd.
(hereinafter referred to as Taishikang), a subsidiary of its medical consumables business, to its controlling shareholder Tianjin Kaierling Group Co.
, Ltd.
at a transaction price of 130 million.
Yuan
.
Public information shows
.
Established in 2011, Taishikang's main business is the production and sales of hemodialysis concentrates, dry hemodialysis powders, and disinfectants
.
From the perspective of financial data, the announcement shows that as of September 30 this year, Taishikang's net assets were 67,985,500 yuan.
In the first three quarters of this year, Taishikang's operating income and net profit were 78,686,700 yuan and 4.
5164 million yuan, respectively
.
Regarding the reason for the sale of Taishikang, Minxiang Pharmaceutical stated that it was due to changes in the market situation of centralized procurement of medical consumables and the company's plan to focus on the pharmaceutical sector
.
In this regard, the industry believes that the divestiture of subsidiaries in recent years has long been the norm for domestic pharmaceutical companies
.
With the continuous release of policies such as national procurement, mass procurement, consistency evaluation, and drug approval reforms, China's pharmaceutical industry is facing increasingly fierce market competition, which has prompted the concentration of China's pharmaceutical industry to continue to increase; As a result, a large number of pharmaceutical companies have also begun to focus on the development of their main business and enhance their core competitiveness by selling or divesting assets that are not in line with their own strategic development
.
In the recent past, in addition to Minxiang Pharmaceutical, a large number of companies are also accelerating their "weight reduction", among which operations such as dissolving subsidiaries and selling equity have continued
.
As some time ago, Renfu Pharmaceutical announced that it intends to liquidate its 2.
52% of Huatai Insurance equity held by 1.
026 billion yuan, corresponding to 102 million shares, and the transfer price is 1.
026 billion yuan
.
The transferee this time is "Anda"
.
It is understood that as early as August 1996, Huatai Insurance conducted an angel round of financing.
For the purpose of this equity transfer, Renfu Medicine stated that it was to implement the "refocusing focus", to promote business focus on asset optimization, and gradually withdraw from the competitive advantage.
Or subdivided areas with weaker synergy
.
It is worth mentioning that it has successively sold business-related assets such as medical services and gender health.
.
In the same month, Eastern Sunshine Technology also issued an announcement stating that it intends to sell 226 million domestic shares to Guangyao Pharmaceutical, and plans to sell 226 million H-share "fully-tradable" shares to Guangyao's wholly-owned subsidiary, Hong Kong Eastern Sunshine
.
The above two transactions totaled 452 million shares, accounting for approximately 51.
41% of Dongyang Sunshine Pharmaceuticals' total share capital
.
The transaction price was 3.
723 billion yuan
.
In addition, Dongyang Sunshine also stated that the company will no longer engage in the production and sales of pharmaceutical-related products; Actively expand new business in the field of new energy such as variable frequency energy storage and new energy vehicles
.
Public information shows that Dongyang Pharmaceutical is a subsidiary of Dongyang Pharmaceutical and has been focusing on drug development, production and drug sales in China.
The products cover Antiviral, endocrine, cardiovascular and other disease treatment fields
.
On August 31 this year, Tosun has issued an announcement revealing that it is planning a major asset sale and intends to transfer to Guangdong Dongyang Pharmaceutical Co.
, Ltd.
and/or its holding subsidiaries It holds no more than 51.
41% equity of Dongyang Sun Pharmaceutical
.
The industry expects that as the concentration of the pharmaceutical industry will continue to increase, market competition will become increasingly fierce; domestic and foreign pharmaceutical companies will continue to accelerate their adjustments to strategic planning, resulting in mergers and acquisitions, Activities such as restructuring will also become more frequent
.
